Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
JP7291369B2 - Visceral fat reducing agent and food composition for reducing visceral fat - Google Patents
[go: Go Back, main page]

JP7291369B2 - Visceral fat reducing agent and food composition for reducing visceral fat - Google Patents

Visceral fat reducing agent and food composition for reducing visceral fat Download PDF

Info

Publication number
JP7291369B2
JP7291369B2 JP2018219120A JP2018219120A JP7291369B2 JP 7291369 B2 JP7291369 B2 JP 7291369B2 JP 2018219120 A JP2018219120 A JP 2018219120A JP 2018219120 A JP2018219120 A JP 2018219120A JP 7291369 B2 JP7291369 B2 JP 7291369B2
Authority
JP
Japan
Prior art keywords
visceral fat
rice
culture
mycelium
pupa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018219120A
Other languages
Japanese (ja)
Other versions
JP2020080708A5 (en
JP2020080708A (en
Inventor
文男 小林
正好 斉藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LA VIE EN SANTE CO., LTD.
Original Assignee
LA VIE EN SANTE CO., LTD.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LA VIE EN SANTE CO., LTD. filed Critical LA VIE EN SANTE CO., LTD.
Priority to JP2018219120A priority Critical patent/JP7291369B2/en
Priority to PCT/JP2019/045406 priority patent/WO2020105675A1/en
Publication of JP2020080708A publication Critical patent/JP2020080708A/en
Publication of JP2020080708A5 publication Critical patent/JP2020080708A5/ja
Application granted granted Critical
Publication of JP7291369B2 publication Critical patent/JP7291369B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • A61K36/062Ascomycota
    • A61K36/066Clavicipitaceae
    • A61K36/068Cordyceps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14Fungi; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Description

NPMD NPMD NITE BP-02800NITE BP-02800

本発明は、サナギタケ(Cordyceps militaris)菌糸体の穀物培養物を有効成分とする内臓脂肪低減剤及び内臓脂肪低減用食品組成物に関する。 TECHNICAL FIELD The present invention relates to a visceral fat-reducing agent and a visceral fat-reducing food composition containing a grain culture of Cordyceps militaris mycelium as an active ingredient.

肥満はさまざまな疾病の発症に関与していることから、日本では、2008年4月より腹囲等を測定する特定検診・特定保健指導(いわゆる「メタボ検診」)が実施されている。特に、内臓脂肪型肥満は、糖尿病、動脈硬化、高脂血症、高血圧、心血管疾患又は脳卒中等の生活習慣病の発症原因の一つとされていることから、内臓脂肪型肥満と診断された場合には、内臓脂肪を低減させるための治療を行うことが重要である。 Since obesity is involved in the onset of various diseases, since April 2008, in Japan, specific medical examinations and specific health guidance (so-called "metabolism examinations") for measuring the waist circumference and the like have been implemented. In particular, visceral fat-type obesity is considered to be one of the causes of lifestyle-related diseases such as diabetes, arteriosclerosis, hyperlipidemia, hypertension, cardiovascular disease, and stroke. In some cases, it is important to carry out treatment to reduce visceral fat.

内臓脂肪型肥満の治療方法としては、主に、摂取カロリーを制限する食事療法と、運動によって脂肪燃焼を図る運動療法とがあるが、これらの療法の効果を高めるために用いられる内臓脂肪低減剤が種々提案されている。例えば、特許文献1には、セイヨウトチノキの樹皮抽出物を有効成分とする内臓脂肪低減剤が開示され、特許文献2には、温州みかんの搾汁粕の酵素処理物が、内臓脂肪の低減作用を有することが記載されている。 Treatment methods for visceral fat-type obesity mainly include diet therapy that restricts calorie intake and exercise therapy that aims to burn fat through exercise. Visceral fat-reducing agents are used to enhance the effects of these therapies. have been proposed. For example, Patent Document 1 discloses a visceral fat-reducing agent containing a horse chestnut bark extract as an active ingredient, and Patent Document 2 discloses that an enzyme-treated product of squeezed lees of Satsuma mandarin orange has a visceral fat-reducing effect. It is described to have

他方、虫草菌とよばれるノムシタケ属(Cordyceps)は、コウモリガ、セミ、カイコ等の昆虫の幼虫に寄生し、子実体である茸を形成させる特異な菌類である。たとえば、冬虫夏草(Cordyceps sinensis)はコウモリガの幼虫に寄生する虫草菌の一種であり、漢方薬の生薬として有名である。また、サナギタケ(Cordyceps militaris)はカイコの幼虫に寄生する虫草菌である。 On the other hand, the genus Cordyceps, which is called thoracic fungus, is a peculiar fungus that parasitizes the larvae of insects such as bat moths, cicadas, and silkworms and forms mushrooms, which are fruiting bodies. For example, Cordyceps sinensis is a type of parasitic fungus that parasitizes bat moth larvae, and is famous as a herbal medicine. Cordyceps militaris is a fungus parasitic on silkworm larvae.

特許第4415063号Patent No. 4415063 特許第5830214号Patent No. 5830214

上述したように、メタボリックシンドロームを解消するため、内臓脂肪を有効かつ迅速に低減させることができ、安全性が高く、安価に入手することができる医薬品や食品等の材料を開発し、提供することが依然として期待されている。 As described above, in order to eliminate metabolic syndrome, it is necessary to develop and provide materials such as medicines and foods that can effectively and quickly reduce visceral fat, are highly safe, and can be obtained at low cost. is still expected.

他方、虫草菌であるサナギタケ(Cordyceps militaris)を、内臓脂肪型肥満の治療や内臓脂肪低減剤として用いることについての検討はこれまでなされておらず、その有効性はまったく不明であった。 On the other hand, the use of Cordyceps militaris, a fungus, as a treatment for visceral fat-type obesity or as a visceral fat-reducing agent has not been studied so far, and its efficacy has been completely unknown.

したがって、本発明は上述した点に鑑みてなされたもので、その目的は、安全性に優れ、低コストで製造することができ、高い内臓脂肪低減効果を示す、内臓脂肪低減剤及び内臓脂肪低減用食品組成物を提供することにある。 Therefore, the present invention has been made in view of the above points, and an object of the present invention is to provide a visceral fat-reducing agent and a visceral fat-reducing agent that are excellent in safety, can be produced at low cost, and exhibit a high visceral fat-reducing effect. It is to provide a food composition for

上記課題を解決するため、本発明の内臓脂肪低減剤は、サナギタケ(Cordyceps militaris)菌糸体の穀物培養物を含有する。 In order to solve the above problems, the visceral fat-reducing agent of the present invention contains a grain culture of Cordyceps militaris mycelium.

この穀物培養物は、後述する実施例で示すように、内臓脂肪量を迅速に減少させることから、内臓脂肪低減剤として用いることができる。さらに、漢方薬の生薬として用いられてきた虫草菌であるサナギタケの菌糸体と食品材料である穀物による培養物を有効成分とするものであるため、安全性が高い。 This cereal culture can be used as a visceral fat-reducing agent because it rapidly reduces the amount of visceral fat, as shown in the examples below. Furthermore, it is highly safe because it contains, as active ingredients, cultures of grains, which are food materials, and the mycelium of Chrysalis chrysalis, a herb that has been used as a crude drug in Chinese herbal medicine.

また、本発明の内臓脂肪低減剤における穀物は、米であることも好ましい。これにより、穀物培養物の原料として好適なものが選択される。 Moreover, it is also preferable that the grain in the visceral fat-reducing agent of the present invention is rice. This allows selection of suitable raw materials for the grain culture.

また、上述したサナギタケ(Cordyceps militaris)が、受託番号:NITE P-02800で特定されるCordyceps militaris KT16514株であることも好ましい。これにより、本発明の有効成分である穀物培養物をもたらす好適なサナギタケ株が選択される。 Moreover, it is also preferable that the above-mentioned pupa mushroom (Cordyceps militaris) is Cordyceps militaris KT16514 strain identified by accession number: NITE BP -02800. This selects suitable pupa strains that yield cereal cultures that are the active ingredient of the present invention.

また、本発明の内臓脂肪低減用食品組成物は、サナギタケ(Cordyceps militaris)菌糸体の穀物培養物を含有する。この穀物培養物は、内臓脂肪量を迅速に減少させることから、内臓脂肪低減用食品組成物として用いることができる。さらに、漢方薬の生薬として用いられてきた虫草菌であるサナギタケの菌糸体と食品材料である穀物による培養物を有効成分とするものであるため、安全性が高く、食品として手軽に経口摂取することができる。 Also, the food composition for reducing visceral fat of the present invention contains a grain culture of Cordyceps militaris mycelium. Since this grain culture rapidly reduces the amount of visceral fat, it can be used as a food composition for reducing visceral fat. Furthermore, since the active ingredient is a culture of grains, which is a food material and the mycelia of the thrombi fungus that has been used as a crude drug in Chinese herbal medicine, it is highly safe and can be easily taken orally as a food. can be done.

また、本発明の内臓脂肪低減用食品組成物における穀物は、米であることも好ましい。これにより、穀物培養物の原料として好適なものが選択される。 Also, the grain in the food composition for reducing visceral fat of the present invention is preferably rice. This allows selection of suitable raw materials for the grain culture.

また、上述したサナギタケ(Cordyceps militaris)が、受託番号:NITE P-02800で特定されるCordyceps militaris KT16514株であることも好ましい。これにより、本発明の有効成分である穀物培養物をもたらす好適なサナギタケ株が選択される。 Moreover, it is also preferable that the above-mentioned pupa mushroom (Cordyceps militaris) is Cordyceps militaris KT16514 strain identified by accession number: NITE BP -02800. This selects suitable pupa strains that yield cereal cultures that are the active ingredient of the present invention.

また、本発明の内臓脂肪低減用食品組成物の製造方法は、穀物原料にサナギタケ(Cordyceps militaris)菌糸体を接種し、培養させて穀物培養物を得ることにより製造される。サナギタケ菌糸体を穀物原料で培養することにより、得られるものであるため、煩雑な工程等を経る必要がなく、比較的低コストで製造することが可能である。 In addition, the method for producing a food composition for reducing visceral fat of the present invention is produced by inoculating a cereal raw material with Cordyceps militaris mycelium and culturing to obtain a cereal culture. Since it is obtained by culturing the pupa mycelium with grain raw materials, it is possible to produce it at a relatively low cost without the need for complicated processes.

本発明によれば、以下のような優れた効果を有する内臓脂肪低減剤及び内臓脂肪低減用食品組成物を提供することができる。
(1)内臓脂肪の減少効果に優れる。
(2)漢方薬の生薬として用いられてきた虫草菌であるサナギタケの菌糸体と食品材料である穀物による培養物を有効成分とするものであるため、安全性が高く、経口摂取できる。
(3)サナギタケの菌糸体を穀物原料で培養することにより製造されるものであるため、化学合成や抽出・精製等の煩雑な工程等を経る必要がなく、簡単且つ低コストに得られる。
According to the present invention, it is possible to provide a visceral fat-reducing agent and a visceral fat-reducing food composition having the following excellent effects.
(1) Excellent effect of reducing visceral fat.
(2) It is highly safe and can be taken orally because it contains, as active ingredients, a culture of the mycelium of pupa pupa, a fungus that has been used as a crude drug in Chinese herbal medicine, and cereals, which is a food material.
(3) Since it is produced by culturing the mycelium of pupa mushrooms with grain raw materials, it can be obtained simply and at low cost without the need for complicated processes such as chemical synthesis, extraction and purification.

本発明の実施形態に係るサナギタケ(Cordyceps militaris)菌糸体の穀物培養物の製造方法を概略的に示すフローチャートである。1 is a flow chart that schematically illustrates a method for producing a cereal culture of Cordyceps militaris mycelium according to an embodiment of the present invention. 実施例3における、(a)対照群及びCM-Rの3日間連日投与群のマウスの体重変化を示すグラフ、及び(b)対照群及びCM-Rの6日間連日投与群のマウスの体重変化を示すグラフである。(a) Graph showing changes in body weight of mice in the control group and group administered CM-R daily for 3 days, and (b) change in body weight of mice in the control group and group administered CM-R daily for 6 days, in Example 3. is a graph showing 実施例4における対照群及び各投与群のマウスの内臓脂肪量の変化を示すグラフである。10 is a graph showing changes in visceral fat mass of mice in the control group and each administration group in Example 4. FIG. 実施例4における対照群及び各投与群のマウスの体重10gあたりの内臓脂肪量の相対重量変化を示すグラフである。10 is a graph showing relative changes in visceral fat mass per 10 g body weight of mice in the control group and each administration group in Example 4. FIG.

まず、図1を参照し、本発明の内臓脂肪低減剤及び内臓脂肪低減用食品組成物に有効成分として含有される、サナギタケ(Cordyceps militaris)菌糸体の穀物培養物の製造方法について説明する。 First, referring to FIG. 1, a method for producing a grain culture of Cordyceps militaris mycelium, which is contained as an active ingredient in the visceral fat-reducing agent and visceral fat-reducing food composition of the present invention, will be described.

図1に示すように、本発明の実施形態にかかるサナギタケ(Cordyceps militaris)菌糸体の穀物培養物の製造方法は、穀物原料を準備する工程S0、穀物原料に水を加え吸水させる工程S1、穀物原料を蒸煮して滅菌する工程S2、蒸煮された穀物原料にサナギタケ菌糸体を接種する工程S3、固体培養を行う工程S4、穀物培養物を得る工程S5及び穀物培養物を凍結乾燥粉末に加工する工程S6から概略構成される。 As shown in FIG. 1, the method for producing a grain culture of Cordyceps militaris mycelia according to the embodiment of the present invention includes step S0 of preparing grain raw materials, step S1 of adding water to the grain raw materials to absorb water, grain Step S2 of steaming and sterilizing the raw material, Step S3 of inoculating the steamed grain raw material with pupa mycelium, Step S4 of performing solid culture, Step S5 of obtaining a grain culture, and Processing the grain culture into a freeze-dried powder. It is roughly configured from step S6.

[穀物原料の準備]
まず、図1に示す穀物原料を準備する工程S0について説明する。本発明における穀物原料としては、デンプン質を主体とする種子原料のことをいい、具体的には、イネ科、マメ科またはその他雑穀類の種子が用いられる。イネ科の植物としては、米、トウモロコシ、小麦、大麦、燕麦及びライ麦等の麦類、キビ、あわ、モロコシ、ヒエ等が挙げられる。また、マメ科の植物としては、大豆、小豆、エンドウマメ、落花生、緑豆等が挙げられ、その他雑穀類の植物としてはソバが挙げられる。これらのうち、本発明に係る穀物原料としては、イネ科の植物の種子が好ましく、内臓脂肪の低減効果及び培養効率等の観点から、米、大麦、及び小麦がより好ましく用いられ、米が特に好ましく用いられる。
[Preparation of grain raw materials]
First, step S0 of preparing grain raw materials shown in FIG. 1 will be described. The cereal raw material in the present invention refers to a seed raw material mainly composed of starch, and specifically, seeds of gramineous, leguminous or other cereals are used. Plants belonging to the Gramineae family include barley such as rice, corn, wheat, barley, oat and rye, millet, millet, sorghum, barnyard millet and the like. Examples of leguminous plants include soybeans, adzuki beans, peas, peanuts, mung beans and the like, and examples of other millet plants include buckwheat. Among these, as the grain raw material according to the present invention, the seeds of plants belonging to the family Gramineae are preferable, and from the viewpoint of the effect of reducing visceral fat and the efficiency of cultivation, rice, barley, and wheat are more preferably used, and rice is particularly used. It is preferably used.

米を穀物原料として用いる際には、後述する培養工程S4での培養効率の観点から、籾殻が除去された状態の米、すなわち、玄米を用いる。また、培養初期の培養速度を向上させる観点から、玄米をさらに精米した精白米を玄米と組み合わせて用いることが好ましい。精白米は玄米よりも速やかにデンプン質からその構成単位のグルコースに分解されるため、米原料に植菌されたばかりの培養初期の微生物をアクティブにし、培養効率を向上させることができる。なお、精白米のみを穀物原料として用いると、栄養成分が除去されすぎているため、培養中期以降の培養効率が低下する傾向にあることから、玄米と精白米を組み合わせて用いることが好ましい。玄米と精白米の配合割合としては、精白米1重量部に対して玄米を1~19重量部(すなわち、重量比で、玄米/精白米=1~19)配合することが好ましく、精白米1重量部に対して玄米を1~9重量部(すなわち、重量比で、玄米/精白米=1~9)配合することがより好ましい。なお、精白米には胚芽米及び無洗米などのさらに磨いた米も含まれる。また、玄米及び精白米はそのままの米粒状で用いることができるが、少なくとも一部を粉砕させて粉末状としたものを用いることも可能である。また、米原料には、米以外の他の穀物原料を配合させたり、必要に応じて糠やグルコース、無機塩類、ビタミン類などを添加することも可能である。 When rice is used as a cereal raw material, rice from which the husk has been removed, that is, unpolished rice is used from the viewpoint of culture efficiency in the culture step S4 described later. In addition, from the viewpoint of improving the culturing speed in the early stage of culturing, it is preferable to use polished rice, which is obtained by further polishing brown rice, in combination with brown rice. In polished rice, the starch is broken down into its constituent units, glucose, more quickly than in brown rice. Therefore, it is possible to activate the microorganisms that have just been inoculated into the raw rice material in the early stage of cultivation, and to improve the cultivation efficiency. If only polished rice is used as a cereal raw material, the nutrient components are removed too much, and the cultivation efficiency tends to decrease after the middle stage of cultivation. Therefore, it is preferable to use a combination of brown rice and polished rice. As for the mixing ratio of brown rice and polished rice, it is preferable to mix 1 to 19 parts by weight of brown rice with 1 part by weight of polished rice (that is, the weight ratio of brown rice/polished rice = 1 to 19). It is more preferable to blend 1 to 9 parts by weight of brown rice with respect to parts by weight (that is, the weight ratio of brown rice/polished rice=1 to 9). Polished rice also includes further polished rice such as germ rice and rinse-free rice. Brown rice and polished rice can be used in the form of rice grains as they are, but it is also possible to use powdered rice obtained by pulverizing at least a portion of the rice. In addition, the rice raw material can be blended with grain raw materials other than rice, and bran, glucose, inorganic salts, vitamins, etc. can be added as necessary.

[吸水処理]
次に、吸水処理工程S1について説明する。本工程では、上述した穀物原料に水を加えるか、穀物原料を水に浸漬させて吸水させる処理が行われる。吸水量は、たとえば、米を穀物原料として用いる場合には、水分が20~60%、好ましくは30~45%となるように調整する。また、大豆を穀物原料として用いる場合には、水分が30~70%、好ましくは40~60%となるように調整する。
[Water absorption treatment]
Next, the water absorption treatment step S1 will be described. In this step, water is added to the above grain raw material, or the grain raw material is immersed in water to absorb water. For example, when rice is used as a cereal raw material, the water absorption is adjusted so that the water content is 20 to 60%, preferably 30 to 45%. When soybeans are used as grain raw materials, the water content is adjusted to 30 to 70%, preferably 40 to 60%.

[蒸煮処理]
次に、蒸煮処理工程S2について説明する。高圧蒸気滅菌器などを用いて、上述の工程で吸水させた穀物原料に水蒸気を当てて蒸煮する。蒸煮処理の温度及び時間は、100~121℃で15分~60分程度が好ましく、15分~30分がより好ましく、121℃で20分程度が特に好ましい。本工程を行うことにより、穀物原料中の雑菌が殺菌され、後の培養工程において、サナギタケ菌糸体による穀物原料の分解、消化及び吸収が行われる。また、この蒸煮処理により、穀物原料中のデンプン質がアルファ化されて分解されやすくなるので、後の培養工程において、穀物原料にサナギタケ菌糸体を効率よく繁殖させることができる。蒸煮が終了した穀物原料は、30~40℃程度にまで放冷させる。これにより、サナギタケ菌糸体を穀物原料に接種することが可能となる。
[Steaming process]
Next, the steaming treatment step S2 will be described. Using a high-pressure steam sterilizer or the like, steam is applied to the grain raw material that has been absorbed in the above-described process, and the raw material is steamed. The temperature and time of the steaming treatment are preferably 100 to 121° C. for about 15 minutes to 60 minutes, more preferably 15 minutes to 30 minutes, and particularly preferably 121° C. for about 20 minutes. By performing this step, various bacteria in the grain raw material are sterilized, and in the subsequent culture step, the grain raw material is decomposed, digested and absorbed by the pupa mycelium. In addition, the steaming process converts the starch in the grain raw material into gelatin and makes it easier to decompose, so that the pupal mushroom mycelium can be efficiently propagated in the grain raw material in the subsequent culture step. Grain raw materials that have been steamed are allowed to cool to about 30 to 40°C. This makes it possible to inoculate cereal raw materials with the pupa mycelium.

[サナギタケ菌糸体の接種]
次に、サナギタケ菌糸体を穀物原料に接種する工程S3について説明する。本工程では、上述の蒸煮・殺菌工程を経て冷却された穀物原料に対し、サナギタケ(Cordyceps militaris)菌糸体を接種する。サナギタケはカイコの蛹等に寄生するノムシタケ科ノムシタケ属に属するいわゆる虫草菌であり、中国、韓国、日本等に広く分布する子のう菌類の一種である。サナギタケ菌糸体の接種にあたっては、事前に液体種菌を準備しておき、スターターとして用いることが好ましい。液体種菌は、特に限定されないが、一例として次のようにして準備することができる。グルコースが3重量%、赤糠が2重量%、大豆粉が0.5重量%、酵母エキスが0.5重量%及びアスパラギン酸ナトリウムが0.2重量%からなる種菌用液体培地120mLを500mLの三角フラスコに入れ、121℃で20分間滅菌し、放冷する。その後、サナギタケの1cm×1cmの菌糸体ディスクを接種し、24℃程度で7日間程度培養することにより液体種菌を得ることができる。
[Inoculation of pupa mycelium]
Next, the step S3 of inoculating the cereal raw material with the pupa mycelium will be described. In this step, the cereal raw material cooled through the steaming and sterilization steps described above is inoculated with Cordyceps militaris mycelium. Sanagitake is a type of ascomycete fungi belonging to the genus Chrysomeliaceae of the family Chrysomeliaceae, which parasitizes the pupae of silkworms and the like, and is a kind of ascomycete that is widely distributed in China, Korea, Japan, and the like. When inoculating the pupa mycelium, it is preferable to prepare a liquid spawn in advance and use it as a starter. The liquid spawn is not particularly limited, but can be prepared as follows as an example. 120 mL of a liquid medium for an inoculum containing 3% by weight of glucose, 2% by weight of red rice bran, 0.5% by weight of soybean flour, 0.5% by weight of yeast extract, and 0.2% by weight of sodium aspartate was added to 500 mL. Place in an Erlenmeyer flask, sterilize at 121° C. for 20 minutes, and allow to cool. Thereafter, a liquid spawn can be obtained by inoculating a 1 cm×1 cm mycelium disc of pupa mushroom and culturing at about 24° C. for about 7 days.

本発明においては、サナギタケとして、Cordyceps militaris KT16514株(受託番号:NITE P-02800)を用いることが好ましい。これにより、内臓脂肪の低減効果に優れる穀物培養物を得ることができる。Cordyceps militaris KT16514株は栃木県内山林で発見された子実体から純粋分離されたサナギタケの菌糸体であり、上述した液体種菌培地のほか、固体培地(組成:玄米100g、酵母エキス3g、水分40%)で培養温度23~27℃、培養期間25~35日間の培養条件にて好適に培養される。また、このCordyceps militaris KT16514株について、ITS-5.8S rDNA領域の塩基配列解析を行ったところ、アポロンDB-FUに対するBLAST検索の結果として、Cordyceps militaris IFO30377株(アクセッションNo.AB070375)との同一性が100%であり、Cordyceps militaris IFO9787株(アクセッションNo.AB070374)との同一性が99.8%であることが判明している。また、国際塩基配列データベースに対するBLAST検索の結果においても、Cordyceps militaris種との相同性が99.6%以上であることが判明している。これらのことから、Cordyceps militaris KT16514株の帰属分類群がCordyceps militaris(L.)Fr.であることが同定されている。 In the present invention, Cordyceps militaris KT16514 strain (accession number: NITE BP -02800) is preferably used as the pupa mushroom. This makes it possible to obtain a cereal culture that is excellent in reducing visceral fat. The Cordyceps militaris KT16514 strain is a mycelium of pupa mushroom that was purely isolated from the fruiting body found in the inner forest of Tochigi Prefecture. at a culture temperature of 23 to 27° C. and a culture period of 25 to 35 days. In addition, when the base sequence of the ITS-5.8S rDNA region of this Cordyceps militaris KT16514 strain was analyzed, a BLAST search against Apollon DB-FU revealed that it was identical to the Cordyceps militaris IFO30377 strain (Accession No. AB070375). It has been found to have 100% sex and 99.8% identity to Cordyceps militaris strain IFO9787 (Accession No. AB070374). Moreover, the result of BLAST search against the international nucleotide sequence database also revealed that the homology with Cordyceps militaris species was 99.6% or more. From these facts, the taxonomic group to which the Cordyceps militaris strain KT16514 belongs is Cordyceps militaris (L.) Fr. has been identified.

サナギタケ菌糸体の接種にあたっては、穀物原料の1~5重量%の量のサナギタケの液体種菌を穀物原料に均一に散布して混合する。サナギタケ菌糸体を穀物原料に接種したのち、よく撹拌してサナギタケ菌糸体を穀物原料全体に分散させることが好ましい。 For the inoculation of the pupa mushroom mycelium, the liquid inoculum of pupa mushroom in an amount of 1 to 5% by weight based on the cereal material is uniformly dispersed and mixed with the cereal material. After inoculating the pupa mycelium into the cereal material, it is preferable to stir well to disperse the pupa mycelium throughout the cereal material.

[培養]
次に、穀物原料に接種したサナギタケ菌糸体による培養を行う工程S4について説明する。本工程では、サナギタケ菌糸体を接種した穀物原料にサナギタケ菌糸体を繁殖させる。サナギタケ菌糸体の培養温度は20~30℃とすることが好ましく、23~25℃とすることがより好ましい。培養期間は2週間~2ヶ月間程度とすることが好ましく、種菌を接種してから7~10日目に混合操作を行って菌糸が均一に全体に蔓延する様にし、培養期間を21日~40日間程度とすることがより好ましい。所定の培養期間が経過し菌糸体が十分に蔓延した時点をサナギタケ菌糸体の穀物原料の培養の終了とする。
[culture]
Next, the step S4 of culturing with the pupa mycelium inoculated into the grain raw material will be described. In this step, the pupa pupa mycelium is propagated on the cereal raw material inoculated with the pupa pupa mycelium. The culture temperature of the pupa mycelium is preferably 20 to 30°C, more preferably 23 to 25°C. The culture period is preferably about 2 weeks to 2 months, and 7 to 10 days after the inoculum is inoculated, a mixing operation is performed so that the mycelium spreads uniformly throughout, and the culture period is 21 days to 21 days. About 40 days is more preferable. Cultivation of the cereal raw material of the pupa mycelium is completed when a predetermined culture period has passed and the mycelium has spread sufficiently.

[穀物培養物]
得られたサナギタケ菌糸体の穀物培養物S5は、穀物原料全体にサナギタケ菌糸体が繁殖蔓延している。この穀物培養物を内臓脂肪低減剤及び内臓脂肪低減用食品組成物として用いるにあたっては、穀物培養物全体を殺菌処理することが好ましい。殺菌処理は公知の方法で行われ、一例として高圧蒸気滅菌器などを用いて、121℃で20分間加熱することにより殺菌される。また、この加熱殺菌処理を行うことにより、サナギタケ菌糸体の穀物培養物は殺菌されると同時に加熱処理されて熱水抽出効果も得られる。
[Grain culture]
In the obtained grain culture S5 of the pupa mycelium, the pupa mycelium propagates over the entire grain raw material. When using this grain culture as a visceral fat-reducing agent and a food composition for reducing visceral fat, it is preferable to sterilize the entire grain culture. The sterilization treatment is carried out by a known method, for example, sterilization is performed by heating at 121° C. for 20 minutes using a high-pressure steam sterilizer or the like. Moreover, by performing this heat sterilization treatment, the cereal culture of the pupal mushroom mycelium is sterilized and at the same time heat-treated to obtain the hot water extraction effect.

[凍結乾燥粉末]
次に、サナギタケ菌糸体の穀物培養物を凍結乾燥粉末に加工する工程S6について説明する。殺菌処理された穀物培養物は、一定の水分を含んだ状態であるが、凍結乾燥させることにより水分が除去され、穀物培養物の乾燥物が得られる。なお、自然乾燥、熱風乾燥又は低温真空乾燥等により乾燥物を得てもよい。得られた穀物培養物の乾燥物を粉砕することにより、取り扱いし易い凍結乾燥粉末を得ることができる。また、得られた粉末を顆粒状や打錠品とすることも可能である。加熱殺菌処理を行い、加熱による水分を除去、または凍結粉砕したものであっても、サナギタケ菌糸体の穀物培養物としての機能は有効に保持されている。このサナギタケ菌糸体の穀物培養物は、このままでも充分な内臓脂肪の低減効果を有している。それゆえ、さらなる抽出や分離精製操作等の煩雑な工程は不要であり、簡単かつ低コストにて完成品を得ることができる。
[Lyophilized powder]
Next, the step S6 of processing the grain culture of the pupa mycelium into a freeze-dried powder will be described. The sterilized grain culture contains a certain amount of water, but the water is removed by freeze-drying to obtain a dried grain culture. A dried product may be obtained by natural drying, hot air drying, low-temperature vacuum drying, or the like. A freeze-dried powder that is easy to handle can be obtained by pulverizing the dried product of the obtained grain culture. It is also possible to make the obtained powder into granules or tablets. Even after heat sterilization, moisture removal by heating, or freezing and pulverization, the function of the pupa mycelium as a grain culture is effectively maintained. This cereal culture of pupa mycelium has a sufficient effect of reducing visceral fat even as it is. Therefore, complicated steps such as further extraction and separation and purification operations are unnecessary, and the finished product can be obtained simply and at low cost.

本発明の内臓脂肪低減剤及び内臓脂肪低減用食品組成物は、上述したサナギタケ菌糸体で培養された穀物培養物を有効成分として含むものであって、経口投与又は摂取することにより、内臓脂肪を迅速に低減する作用を有する。本発明の内臓脂肪低減剤の投与量は、目標とする低減量又は他の運動やカロリー制限等の療法の内容、投与方法、年齢などによって変化するので一概には規定できないが、通常一日の経口投与量は、サナギタケ菌糸体の穀物培養物として約10~1000mg/kg体重であり、好ましくは約25~500mg/kg体重であり、さらに好ましくは約50~300mg/kg体重であり、これを投与開始より1~3回に分割して投与すればよい。 The visceral fat-reducing agent and visceral fat-reducing food composition of the present invention contain, as an active ingredient, the grain culture cultured with the above-described pupa mushroom mycelium, and are orally administered or ingested to reduce visceral fat. It has a rapid reducing action. The dosage of the visceral fat-reducing agent of the present invention varies depending on the target reduction amount or other therapy such as exercise or calorie restriction, administration method, age, etc., so it cannot be categorically defined, but it is usually a daily dose. The oral dose is about 10 to 1000 mg/kg body weight, preferably about 25 to 500 mg/kg body weight, more preferably about 50 to 300 mg/kg body weight as a grain culture of pupa mycelium, It may be administered in 1 to 3 divided doses from the start of administration.

本発明の内臓脂肪低減剤は、従来慣用されている方法により種々の形態に調製することができる。この場合、通常製剤用の担体や賦形剤など、医薬品の添加剤として許容されている添加剤を用いて製剤化することができる。また、本発明に係るサナギタケ菌糸体の穀物培養物のバイオアベイラビリティーや安定性を向上させるために、マイクロカプセル、微粉末化、シクロデキストリン等を用いた包接化などの製剤技術を含むドラッグデリバリーシステムを用いることもできる。 The visceral fat-reducing agent of the present invention can be prepared in various forms by conventional methods. In this case, it can be formulated using additives that are generally accepted as pharmaceutical additives, such as carriers and excipients for formulations. In addition, in order to improve the bioavailability and stability of the grain culture of the pupa mycelium according to the present invention, drug delivery including formulation techniques such as microcapsules, micronization, clathration using cyclodextrin, etc. system can also be used.

さらに、上記内臓脂肪低減剤は、錠剤、顆粒剤、カプセル剤又は内服用液剤等の形態で用いることができるが、消化管からの吸収に適した形態で用いることが好ましい。また、流通性、保存性などの理由により所望される形態での製剤を提供する場合にも従来の製剤技術を用いることができる。 Furthermore, the visceral fat-reducing agent can be used in the form of tablets, granules, capsules, internal liquid preparations, etc., and is preferably used in a form suitable for absorption from the gastrointestinal tract. Conventional formulation techniques can also be used to provide formulations in desired forms for reasons such as distribution and storage stability.

また、本発明の内臓脂肪低減用食品組成物は、錠剤やカプセル剤、顆粒剤、シロップ剤などのサプリメント形態、飲料、アメやガム、チョコレート等の菓子、パン、粥、シリアル、麺類、ゼリー、スープ、乳製品、調味料等のあらゆる形態にて食品組成物として用いることができる。このように食品組成物として用いる際には、本発明の有効成分の効能に影響を与えない範囲において、他の有効成分や、ビタミン、ミネラル若しくはアミノ酸等の栄養素等を種々組み合わせることも可能である。本発明の食品組成物から展開される食品には、サプリメント、健康食品、機能性食品、特定保健用食品等が含まれる。また、本発明の食品組成物の1日あたりの摂取量は、上述のサナギタケ菌糸体の穀物培養物として約10~1000mg/kg体重とすることが好ましく、約25~500mg/kg体重とすることがより好ましく、さらに約50~300mg/kg体重とすることが好ましく、これを1~3回に分割して摂取することが好ましい。 In addition, the food composition for reducing visceral fat of the present invention can be used in the form of supplements such as tablets, capsules, granules, and syrups, beverages, sweets such as candy, gum, and chocolate, bread, porridge, cereals, noodles, jelly, It can be used as a food composition in all forms such as soups, dairy products and seasonings. When used as a food composition in this way, it is possible to combine various other active ingredients, nutrients such as vitamins, minerals, amino acids, etc. within the range that does not affect the efficacy of the active ingredients of the present invention. . Foods developed from the food composition of the present invention include supplements, health foods, functional foods, foods for specified health uses, and the like. In addition, the daily intake of the food composition of the present invention is preferably about 10 to 1000 mg/kg body weight, and about 25 to 500 mg/kg body weight, as the grain culture of the above-mentioned pupa mushroom mycelium. is more preferable, and about 50 to 300 mg/kg body weight is more preferable, and it is preferable to divide this into 1 to 3 times.

次に、本発明を実施例によりさらに詳細に説明するが、本発明は、これらの実施例によってなんら限定されるものではない。 Next, the present invention will be described in more detail with reference to Examples, but the present invention is not limited by these Examples.

[実施例1]
1.サナギタケ(Cordyceps militaris)の液体種菌の調製
500mLの三角フラスコに表1に示す液体種菌培地120mLを入れ、121℃で20分間加熱して滅菌処理を行った。放冷後、1cm×1cmの保存用種菌(Cordyceps militaris KT16514株)の菌糸体ディスクを接種し、24℃で7日間培養して液体種菌とした。このCordyceps militaris KT16514株は本発明者(小林文男)により純粋分離されたサナギタケ株であり、受託番号:NITE P-02800として、独立行政法人製品評価技術基盤機構 特許微生物寄託センターに寄託されている。また、このCordyceps militaris KT16514株について、ITS-5.8S rDNA領域の塩基配列解析を行った結果、帰属分類群がCordyceps militaris(L.)Fr.であることが確認されている。
[Example 1]
1. Preparation of Liquid Inoculum of Cordyceps militaris 120 mL of the liquid inoculum medium shown in Table 1 was placed in a 500 mL Erlenmeyer flask and sterilized by heating at 121° C. for 20 minutes. After standing to cool, a 1 cm×1 cm storage seed (Cordyceps militaris strain KT16514) mycelium disc was inoculated and cultured at 24° C. for 7 days to obtain a liquid seed. This Cordyceps militaris KT16514 strain is a pupa mushroom strain purely isolated by the present inventor (Fumio Kobayashi), and has been deposited with the National Institute of Technology and Evaluation, Patent Microorganisms Depositary under the accession number: NITE BP -02800. . In addition, the ITS-5.8S rDNA region of this Cordyceps militaris KT16514 strain was subjected to nucleotide sequence analysis, and as a result, the belonging taxonomic group was Cordyceps militaris (L.) Fr. It has been confirmed that

Figure 0007291369000001
Figure 0007291369000001

[実施例2]
2.サナギタケ(Cordyceps militaris)菌糸体の米培養物の調製
本実施例では、培養原料の穀物として、玄米と精白米を混合した米原料を用いた。玄米と精白米との混合割合は、重量比で玄米:精白米=9:1とした。流通している市販の米の水分含量は約12%であるので、米原料の水分含量が約40%となるように水を加えて吸水させた。具体的には1000gの米原料あたり、400mLの比率で水を加え吸水させた原料1000gを耐熱性培養袋に計量充填した。その後、121℃で20分間加熱して、米原料の蒸煮処理及び滅菌処理を行った。米原料を放冷したのち、実施例1で得られたCordyceps militaris KT16514株の液体種菌を米原料の3重量%となるように米原料に無菌的に混合接種した。24℃で30日間固体培養した後、121℃で20分間加熱して抽出滅菌処理を行い、更に凍結乾燥し粉砕して粉末化した。このようにして本発明のサナギタケ菌糸体の米培養物が得られた(以下、「CM-R」とも表記する。)。この米培養物について、栄養表示成分、重金属及び微生物にかかる分析試験を行った。結果を以下表2に示す。
[Example 2]
2. Preparation of rice culture of Cordyceps militaris mycelium In this example, a rice raw material obtained by mixing brown rice and polished rice was used as the grain of the culture raw material. The mixing ratio of the brown rice and the polished rice was 9:1 by weight. Since the moisture content of commercially available rice is about 12%, water was added to make the rice raw material absorb water so that the moisture content was about 40%. Specifically, 1000 g of raw material, which was made to absorb water by adding water at a rate of 400 mL per 1000 g of rice raw material, was weighed and filled in a heat-resistant culture bag. Thereafter, the raw rice material was steamed and sterilized by heating at 121° C. for 20 minutes. After the raw rice material was allowed to cool, the liquid inoculum of the Cordyceps militaris KT16514 strain obtained in Example 1 was aseptically mixed and inoculated into the raw rice material so as to be 3% by weight of the raw rice material. After solid culture at 24° C. for 30 days, extraction sterilization was performed by heating at 121° C. for 20 minutes, followed by freeze-drying and crushing into powder. Thus, a rice culture of the pupa mycelium of the present invention was obtained (hereinafter also referred to as "CM-R"). This rice culture was analyzed for nutritional labeling components, heavy metals and microorganisms. The results are shown in Table 2 below.

Figure 0007291369000002
Figure 0007291369000002

[実施例3]
3.サナギタケ菌糸体の米培養物の投与による安全性の検討
サナギタケ菌糸体の米培養物(CM-R)の安全性を検証するため、実施例2で得たCM-Rをマウスに連日投与し、体重測定及び臓器等の状態を調査した。具体的には、次のようにして試験を行った。7週齢のICR雄マウス(日本エスエルシー株式会社)を50匹入手し、1週間程度馴化させた後、以下表3に示すように、5匹ずつ10群に分けた。8週齢となったICR雄マウスに対し、実施例2で得たCM-Rをマウスの体重1kg当たり25mg、50mg、100mg及び200mg/kgとなるようにそれぞれ蒸留水にて調整し、マウス用の胃ゾンデを用いて各投与群のマウスに経口投与した。投与総量は0.2mL/回とし、また対照群には同量の蒸留水を投与した。投与期間は1日1回で連日3日間および連日6日間とし、投与期間中、午後2時から4時までのマウス空腹時かつ投与前にマウスの体重測定を行った。また、最終投与24時間後に動物用吸入麻酔剤(イソフル:ゾエティス・ジャパン株式会社製品)の過剰吸入による安楽死を実施し、マウスの外観を検査した。引き続いて解剖を実施し、各臓器の位置、形状、出血及び癒着の有無を検査した。
[Example 3]
3. Examination of safety by administration of rice culture of pupa mycelium In order to verify the safety of the rice culture of pupa mycelium (CM-R), the CM-R obtained in Example 2 was administered to mice every day, Body weight was measured and conditions such as organs were investigated. Specifically, the test was conducted as follows. Fifty 7-week-old ICR male mice (Japan SLC, Inc.) were obtained, acclimatized for about one week, and divided into 10 groups of 5 mice each as shown in Table 3 below. The CM-R obtained in Example 2 was adjusted to 25 mg, 50 mg, 100 mg and 200 mg/kg of mouse body weight for 8-week-old ICR male mice with distilled water. was orally administered to mice in each administration group using a gastric probe. The total amount administered was 0.2 mL/time, and the same amount of distilled water was administered to the control group. The administration period was once a day for 3 consecutive days and 6 consecutive days. During the administration period, the mice were fasted from 2:00 pm to 4:00 pm and weighed before administration. In addition, 24 hours after the final administration, euthanasia was performed by excessive inhalation of an inhalation anesthetic for animals (Isoflur: product of Zoetis Japan Co., Ltd.), and the appearance of the mice was examined. Subsequently, dissection was performed, and the position and shape of each organ, and the presence or absence of bleeding and adhesion were examined.

Figure 0007291369000003
Figure 0007291369000003

CM-Rの経口投与期間中におけるマウスの体重の変化を図2に示す。図2(a)は3日間投与群のグラフであり、図2(b)は6日間投与群のグラフである。3~6日間の連続投与による顕著な体重の増減は認められず、各投与群において体重の自然増加(1.8%~4.7%)が認められた。具体的には、CM-Rの3日間投与群では、対照群で1.8%の体重増加がみられ、100mg/kg投与群を除き、25mg/kgから200mg/kg投与群では4.1~4.7%の体重増加がみられた。CM-Rの6日間投与群においても対照群で1.8%の体重増加がみられ、25mg/kgから200mg/kg投与各群では0.9~3.0%の体重増加がみられた。他方、投与期間中のマウスには投与群及び対照群いずれのマウスも運動性、行動及び食欲に異常がみられず、連日投与後にも体毛の汚れ及び下痢などの異常は認められなかった。また、解剖を行って各臓器の位置、形状、出血、癒着の有無を検査したところ、投与群及び対照群いずれのマウスについても、各臓器の位置、形状、出血及び癒着等の異常はみられなかった。 FIG. 2 shows changes in body weight of mice during oral administration of CM-R. FIG. 2(a) is a graph for the 3-day administration group, and FIG. 2(b) is a graph for the 6-day administration group. No significant increase or decrease in body weight was observed due to continuous administration for 3 to 6 days, and a spontaneous increase in body weight (1.8% to 4.7%) was observed in each administration group. Specifically, in the CM-R administration group for 3 days, the control group showed a weight gain of 1.8%, except for the 100 mg/kg administration group, and 4.1 in the 25 mg/kg to 200 mg/kg administration group. A body weight gain of ~4.7% was observed. In the CM-R administration group for 6 days, a 1.8% weight gain was observed in the control group, and 0.9 to 3.0% weight gain was observed in each of the 25 mg/kg to 200 mg/kg administration groups. . On the other hand, no abnormalities in motility, behavior and appetite were observed in mice in both the administration group and the control group during the administration period, and no abnormalities such as staining of body hair and diarrhea were observed even after daily administration. In addition, when dissection was performed and the position and shape of each organ and the presence or absence of bleeding and adhesion were examined, no abnormalities such as the position, shape, bleeding and adhesion of each organ were observed in both the administration group and the control group. I didn't.

これらの結果より、CM-Rの25mg/kg、50mg/kg、100mg/kgおよび200mg/kgの3日間投与と6日間投与について特記すべき異常はみられなかった。これにより、サナギタケ菌糸体の米培養物は安全性が高いものであることが確認された。 From these results, no notable abnormalities were observed in 3-day administration and 6-day administration of 25 mg/kg, 50 mg/kg, 100 mg/kg and 200 mg/kg of CM-R. This confirmed that the rice culture of the pupa mycelium is highly safe.

[実施例4]
4.サナギタケ菌糸体の米培養物による内臓脂肪の低減
実施例3において、サナギタケ菌糸体の米培養物(CM-R)を連日3日間投与した試験群及び対照群のマウスの各個体について、安楽死後、精巣周囲脂肪を採取し、各試験群及び対照群ごとの平均値を求めた。精巣周囲脂肪は、腹腔内脂肪の代表的なものとされており、他の組織から独立した脂肪組織として採取可能である。結果を図3及び図4に示す。
[Example 4]
4. Reduction of visceral fat by rice culture of pupa mycelium Peri-testicular fat was collected, and the average value for each test group and control group was determined. Peri-testicular fat is a representative of intra-abdominal fat, and can be collected as an adipose tissue independent of other tissues. The results are shown in FIGS. 3 and 4. FIG.

図3のグラフの縦軸は測定した脂肪組織の重量(mg)であり、棒グラフの各バーは、左側から対照群(0mg/kg)、CM-R 25mg/kg投与群、CM-R 50mg/kg投与群、CM-R 100mg/kg投与群及びCM-R 200mg/kg投与群を示している。図3に示すように、この結果によれば、対照群と比べて、CM-Rを投与した群では、内臓脂肪量が低減することが示された。具体的には、対照群の精巣周囲脂肪重量の平均値が805mgであったのに対して、CM-Rを25mg/kg投与した試験群の精巣周囲脂肪重量の平均値は790mgに留まったものの、CM-R 50mg/kg投与群の平均値は632mgまで減少(対照群の重量の78.5%にまで減少)し、CM-R 100mg/kg投与では698mgに減少(対照群の重量の86.7%に減少)、CM-R 200mg/kg投与群では564mgまで減少(対照群の重量の70.1%にまで減少)した。このうち、特にCM-R 200mg/kg投与群は有意差を伴う減少(P<0.05)であった。このように、CM-R、すなわち、サナギタケ菌糸体の米培養物の投与によって、内臓脂肪が低減することがわかった。 The vertical axis of the graph in FIG. 3 is the measured adipose tissue weight (mg), and each bar in the bar graph indicates, from the left, the control group (0 mg/kg), the CM-R 25 mg/kg administration group, and the CM-R 50 mg/kg. A kg administration group, a CM-R 100 mg/kg administration group, and a CM-R 200 mg/kg administration group are shown. As shown in FIG. 3, the results showed that the visceral fat mass was reduced in the CM-R-administered group compared to the control group. Specifically, while the average peri-testicular fat weight in the control group was 805 mg, the average per-testicular fat weight in the test group to which CM-R was administered at 25 mg/kg was only 790 mg. , the mean value of the CM-R 50 mg/kg administration group decreased to 632 mg (78.5% of the control group weight), and the CM-R 100 mg/kg administration decreased to 698 mg (86% of the control group weight). 7%), and decreased to 564 mg in the CM-R 200 mg/kg administration group (reduced to 70.1% of the weight of the control group). Among them, the CM-R 200 mg/kg administration group showed a significant decrease (P<0.05). Thus, it was found that administration of CM-R, a rice culture of pupa mycelium, reduced visceral fat.

図4のグラフは、各試験群及び対照群のマウス体重10gあたりの相対重量変化を示している。通常、精巣周囲脂肪組織の重量はマウスの週齢及び体重と相関している。グラフの縦軸はマウス体重10gあたりの精巣脂肪組織の重量(mg)であり、棒グラフの各バーは、左側から対照群(0mg/kg)、CM-R 25mg/kg投与群、CM-R 50mg/kg投与群、CM-R 100mg/kg投与群及びCM-R 200mg/kg投与群を示している。この結果によれば、対照群と比べて、CM-Rを投与した群では、体重に占める内臓脂肪量が低減することが示された。具体的には、マウス体重10gあたりの対照群の精巣周囲脂肪重量の平均値が207mgであったのに対して、CM-Rを25mg/kg投与した試験群の平均値は193mgに留まったものの、CM-R 50mg/kg投与群の平均値は156mgまで減少(対照群の重量の75.4%にまで減少)し、CM-R 100mg/kg投与では179mgに減少(対照群の重量の87.3%に減少)、CM-R 200mg/kg投与群では143mgまで減少(対照群の重量の69.1%にまで減少)した。このうち、特にCM-R 50mg/kg投与群及び200mg/kg投与群は有意差を伴う減少(P<0.05)であった。この結果より、CM-Rを投与したことにより、体重全体が減少するのではなく、内臓脂肪が選択的に低減されたことがわかった。このように、CM-R、すなわち、サナギタケ菌糸体の米培養物の投与によって、内臓脂肪が低減することがわかった。 The graph in FIG. 4 shows the relative weight change per 10 g of mouse body weight in each test group and control group. Generally, the weight of the peri-testicular adipose tissue correlates with the age and weight of the mice. The vertical axis of the graph is the weight (mg) of testicular adipose tissue per 10 g of mouse body weight, and each bar in the bar graph indicates, from the left, the control group (0 mg/kg), the CM-R 25 mg/kg administration group, and the CM-R 50 mg. /kg administration group, CM-R 100 mg/kg administration group and CM-R 200 mg/kg administration group. According to the results, it was shown that the amount of visceral fat in the body weight was reduced in the CM-R-administered group as compared with the control group. Specifically, the average peri-testicular fat weight of the control group per 10 g of mouse body weight was 207 mg, while the average value of the test group administered 25 mg/kg of CM-R remained at 193 mg. , the mean value of the CM-R 50 mg/kg administration group decreased to 156 mg (75.4% of the weight of the control group), and that of the CM-R 100 mg/kg administration decreased to 179 mg (87% of the weight of the control group). 3%), and decreased to 143 mg in the CM-R 200 mg/kg administration group (reduced to 69.1% of the weight of the control group). Among them, the CM-R 50 mg/kg administration group and the CM-R 200 mg/kg administration group showed a significant decrease (P<0.05). From this result, it was found that administration of CM-R selectively reduced visceral fat rather than overall body weight. Thus, it was found that administration of CM-R, a rice culture of pupa mycelium, reduced visceral fat.

本発明は、上記の実施形態又は実施例に限定されるものでなく、特許請求の範囲に記載された発明の要旨を逸脱しない範囲内での種々、設計変更した形態も技術的範囲に含むものである。 The present invention is not limited to the above-described embodiments or examples, and includes various design changes within the scope of the invention within the scope of the invention described in the claims. .

NITE P-02800
NITE B P-02800

Claims (4)

サナギタケ(Cordyceps militaris)菌糸体の米の固体培養物を含有し、
前記米は、精白米1重量部に対して玄米を1~19重量部配合したものであることを特徴とする内臓脂肪低減剤。
containing a solid rice culture of Cordyceps militaris mycelium ;
The visceral fat-reducing agent , wherein the rice comprises 1 to 19 parts by weight of brown rice per 1 part by weight of polished rice .
前記サナギタケ(Cordyceps militaris)が、受託番号:NITE BP-02800で特定されるCordyceps militaris KT16514株であることを特徴とする請求項に記載の内臓脂肪低減剤。 2. The visceral fat reducing agent according to claim 1 , wherein the pupa mushroom (Cordyceps militaris) is Cordyceps militaris KT16514 strain identified by accession number: NITE BP-02800. サナギタケ(Cordyceps militaris)菌糸体の米の固体培養物を含有し、
前記米は、精白米1重量部に対して玄米を1~19重量部配合したものであることを特徴とする内臓脂肪低減用食品組成物。
containing a solid rice culture of Cordyceps militaris mycelium ;
A food composition for reducing visceral fat , wherein the rice is a mixture of 1 to 19 parts by weight of brown rice per 1 part by weight of polished rice .
前記サナギタケ(Cordyceps militaris)が、受託番号:NITE BP-02800で特定されるCordyceps militaris KT16514株であることを特徴とする請求項に記載の内臓脂肪低減用食品組成物。
The food composition for reducing visceral fat according to claim 3 , wherein the pupa mushroom (Cordyceps militaris) is Cordyceps militaris KT16514 strain identified by accession number: NITE BP-02800.
JP2018219120A 2018-11-22 2018-11-22 Visceral fat reducing agent and food composition for reducing visceral fat Active JP7291369B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2018219120A JP7291369B2 (en) 2018-11-22 2018-11-22 Visceral fat reducing agent and food composition for reducing visceral fat
PCT/JP2019/045406 WO2020105675A1 (en) 2018-11-22 2019-11-20 Visceral fat reduction agent and food composition for reducing visceral fat

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2018219120A JP7291369B2 (en) 2018-11-22 2018-11-22 Visceral fat reducing agent and food composition for reducing visceral fat

Publications (3)

Publication Number Publication Date
JP2020080708A JP2020080708A (en) 2020-06-04
JP2020080708A5 JP2020080708A5 (en) 2021-12-16
JP7291369B2 true JP7291369B2 (en) 2023-06-15

Family

ID=70773840

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018219120A Active JP7291369B2 (en) 2018-11-22 2018-11-22 Visceral fat reducing agent and food composition for reducing visceral fat

Country Status (2)

Country Link
JP (1) JP7291369B2 (en)
WO (1) WO2020105675A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007135422A (en) 2005-11-15 2007-06-07 Yukimori Kondo Method for producing fruit body of insect parasitic fungus
JP2009247254A (en) 2008-04-04 2009-10-29 Hosoda Shc:Kk Health drink

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180119940A (en) * 2017-04-26 2018-11-05 (주)아모레퍼시픽 Method for extract of manufacturing fermentated tea and extract of fermentated tea prepared therefrom

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007135422A (en) 2005-11-15 2007-06-07 Yukimori Kondo Method for producing fruit body of insect parasitic fungus
JP2009247254A (en) 2008-04-04 2009-10-29 Hosoda Shc:Kk Health drink

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LEE, S.M., et al.,Effects of Cordyceps militaris cultivated on rice on lipid metabolism in rats fed high fat-cholester,J. Food Sci. Nutr. (2006) Vol.11, pp.36-41,ISSN:1226-332X

Also Published As

Publication number Publication date
WO2020105675A1 (en) 2020-05-28
JP2020080708A (en) 2020-06-04

Similar Documents

Publication Publication Date Title
CN105087423B (en) Novel Bei Laisi bacillus CJBV and the bactericidal composition containing it
KR101252639B1 (en) Composition for Prevention or Treatment of Osteoporosis Comprising Ssanghwatang and Fermentation Product Thereof with Lactic Acid Bacteria
KR101177245B1 (en) Dietary supplement containing fermented rice bran of brown rice and manufacturing method thereof
KR100975140B1 (en) Herbal Medicine or Grains Fermentation Method
KR102130332B1 (en) Health fuctional food composition for preventing or improving liver diseases comprising Gastrodia elata and larva
CN104547521A (en) Compound fermentation traditional Chinese medicine for enhancing immunity of livestock and poultry and preparation method of compound fermentation traditional Chinese medicine
JPWO2006093267A1 (en) Fermentation composition having immunomodulatory action
CN109420046A (en) A kind of method of herbal prescription preparation prevention and treatment porcine hyperthermia drug
CN113797321B (en) Composition for preventing or treating weight loss specific metabolic syndrome containing mixed grain fermentation enzyme as effective component
JP7007663B2 (en) Kuro-moji extract
KR101493954B1 (en) Multifunctional soybean byproducts fermented with Aspergillus species, method for preparing the same and use of the same
KR101192673B1 (en) Method for fermentation of mixed grains using fermentation micro-organisms (fm) and mass production of fermented grains
JP7291369B2 (en) Visceral fat reducing agent and food composition for reducing visceral fat
JP4109572B2 (en) Cordyceps mycelium culture method and composition
AU1502101A (en) Augmentation method for antitumor activity of substance containing amygdalin, composition containing augmented amygdalin contained substance, method for assessing antitumor efficacy of treatment for amygdalin contained substance and method for assessing antitumor substance containing amygdalin
JP2020005539A (en) Culture medium, method for obtaining useful substance, useful substance and use therefor
JP7228225B2 (en) Radiation injury suppression, alleviation, or therapeutic agent and food composition for suppression, alleviation, or improvement of radiation injury
KR102271933B1 (en) Manufacturing method of composition comprising mushroom mycelia for glucose level
CN102919847B (en) Nutrient rice noodles capable of preventing osteoporosis and preparation method of same
KR20010087699A (en) The cultivation method of Cordyceps sinensis et al. having a high concentration of gamma-aminobutyric acid
KR20200059870A (en) Composition comprising fungi mycelia complex and red rice for rice cooking
JP7686892B2 (en) Composition for improving fatigue, sleep disorders, eye fatigue and menopausal symptoms
JP3373821B2 (en) Mushroom composition for eating and drinking and method for producing the same
CN114540202B (en) Preparation method of sparassis crispa dry powder, physiological function active agent and application thereof
KR102496034B1 (en) Novel Inonotus obliquus GUC111 and antidiabetic composition comprising it

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20181122

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20190528

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230216

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230523

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230529

R150 Certificate of patent or registration of utility model

Ref document number: 7291369

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250